	US 12,269,886 B2
	Tetravalent bispecific antibody against PD-1 and PD-L1
Zhenping Zhu, Shanghai (CN); Jie Zhao, Shanghai (CN); Haomin Huang, Shanghai (CN); and Mengying Xia, Shanghai (CN)
Assigned to Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Shanghai (CN)
Appl. No. 17/615,475
Filed by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Shanghai (CN)
PCT Filed Apr. 19, 2021, PCT No. PCT/CN2021/088154 § 371(c)(1), (2) Date Nov. 30, 2021, PCT Pub. No. WO2021/227782, PCT Pub. Date Nov. 18, 2021.
Claims priority of application No. PCT/CN2020/090442 (WO), filed on May 15, 2020.
Prior Publication US 2023/0076124 A1, Mar. 9, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C12N 5/10 (2006.01); C12N 15/00 (2006.01); C12N 15/11 (2006.01)

CPC C07K 16/2827 (2013.01) [A61P 35/00 (2018.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/35 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C12N 5/10 (2013.01); C12N 15/00 (2013.01); C12N 15/11 (2013.01); C12N 2510/00 (2013.01); C12N 2800/00 (2013.01)]

10 Claims

1. A tetravalent bispecific antibody against PD-1 and PD-L1, characterized in that, the tetravalent bispecific antibody comprises two identical polypeptide chains and four common light chains, wherein each of the two identical polypeptide chains has the amino acid sequence as shown in SEQ ID NO: 29 or SEQ ID NO: 31, and each of the four common light chains has the amino acid sequence as shown in SEQ ID NO: 15.